Business
Faron Announces Top-Line 12-Month Survival Results
Faron Announces Top-Line 12-Month Survival Results.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \n \n \n Faron Pharmaceuticals Ltd\n \n \n \n \n (\"Faron\" or \"Company\")\n \n \n \n \n \n \n \n \n \n Faron Pharmaceuticals Announces Top-Line 12-Month Survival Results Across 10 Advanced Solid Tumors\n \n \n \n \n \n \n \n \n ·\n \n 65% of patients who benefited from treatment with\n \n \n bexmarilimab\n \n \n were alive at 12-months compared to 11% for patients who did not benefit from treatment\n \n \n \n ·\n \n The\n \n \n strongest\n \n \n survival benefit was seen in checkpoint refractory melanoma and cholangiocarcinoma where 12\n \n \n -\n \n \n month survival was 100%\n \n \n among patients who benefited from bexmarilimab treatment and\n \n \n 0%\n \n \n for patients who did not benefit from treatment\n \n \n \n ·\n \n Analysis includes heavily pre-treated, advanced disease patients from 10 solid tumor cohorts\n \n \n \n ·\n \n Treatment with\n \n \n bexmarilimab\n \n \n continues to be well tolerated with no treatment related adverse events resulting\n \n \n in a decrease or modification of dosing\n \n \n \n \n \n \n \n Company Announcement, June 15, 2022 at 02:00 AM (EST) / 07:00 AM (BST) / 09:00 AM (EEST)\n \n \n \n \n Insider information\n \n \n \n \n \n \n \n \n \n TURKU, FINLAND / BOSTON, MA\n \n - Faron Pharmaceuticals Ltd (\n AIM: FARN, First North: FARON\n ), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation,\n today announces 12-month top-line overall survival results from its Phase\n I/II MATINS (Macrophage Antibody To INhibit immune Suppression) study investigating the safety and efficacy of bexmarilimab\n monotherapy\n in ten different hard-to-treat metastatic or inoperable solid tumor cohorts. The analysis showed that 65% (11/17) of patients who\n benefited from treatment with\n bexmarilimab\n (\n partial response + stable disease rate)\n were alive at 12-months compared to 11% (8/73) of patients who did not benefit from treatment. The strongest survival benefit was seen in checkpoint refractory melanoma and cholangiocarcinoma where 12-month survival was 100% among patients who benefited from bexmarilimab treatment and 0% for patients who did not benefit from treatment. The analysis includes 90 patients from the trial who received three courses of treatment an...